促甲状腺激素受体抗体(TRAb)测定的临床价值

研究促甲状腺激素受体抗体(TRAb)测定在甲状腺病症诊断中的临床价值。方法 将参与本次研究43例健康者作为本次对比对象,归为对照组,同时将接收45例单纯甲肿患者、57例甲亢患者、48例甲减患者均作为本次研究对象,分别归为甲肿组、甲亢组、甲减组,所有参与者均接受TRAb测定,统计并对比参与者阳性率及具体TRAb水平,分析其关联性。结果 甲亢组、甲减组TRAb阳性率与对照组差异显著,P<0.05。甲肿组TRAb阳性率与对照组无较大差异,TRAb水平与T3、T4、FT3、FT4、TSH、TRAb均无明显关联,P>0.05。结论 通过TRAb测定可实现甲亢、甲减病症诊断、鉴别诊断等,同时还可根据其具体水平值变化进行病症发展阶段、预后状况评估等,检测价值显著。因此,在进行甲亢、甲减病症诊治过程中还需加强对TRAb测定重视度,促进诊治效果均可不断提升。

轻度缺碘地区全民食盐加碘后5～15年单纯性甲肿住院情况分析

[目的 ]评价全民食盐加碘对单纯性甲肿的影响。[方法 ]采用回顾性调查方法对 1989— 1999年住院单纯性甲肿病例进行收集和分析。[结果 ]全民食盐加碘后 5～ 15年单纯性甲肿住院 2 4例 ,占住院甲状腺疾病的 4 1%。其中男 4例 ,女 2 0例。[结论 ]全民食盐加碘 5～ 15年后单纯性甲肿住院情况基本没有变化。

可溶性细胞间粘附分子—1放免法在三种甲状腺疾病中初步临床应用

目的：目前，国内外尚未见有关可溶性细胞间粘附分子-1（sICAM-1）放免法（RIA）的报道，为此用本室研制的^125I-sICAM-1RIA，检测正常人和三种甲状腺疾病（单纯性甲肿，Graves'病或Hashimoto'病）患者血清sICAM-1水平。方法：用^125I-sICAM-1 RIA，检测400例正常人以及1020例患有单纯性甲状腺肿、Graves'病或者Hashimoto'病患者血清sICAM-1水平。结果：正常组sICAM-1水平（x^-±s）为：168.43±36.23μg/L。正常组与单纯性甲肿组间无显著性差别（P>0.05），而自身免疫性甲状腺疾病（Graves'病和Hashimoto'病）均分别明显高于正常组或单纯性甲肿组（P<0.05）。三种治疗均可降低Graves'病患者血清sICAM-1水平（P<0.05）。药物治疗后甲状腺功能恢复正常的Graves'病组sICAM-1水平明显低于Graves'病停药复发组（P<0.05）。结论：^125I-sICAM-1 RIA可用于检测自身免疫性甲状腺疾病；血清sICAM-1水平可作为自身免疫性甲状腺疾病诊断的一个指标，及在评价Granes'病的疗效、停药或者复发等方面的一个指标。

A preliminary clinical application of sICAM-1 RIA in three kinds of thyroid disease

To examine serum levels of sICAM 1 from normal controls and patients with thyroid diseases (simple goitre, Graves’ disease or Hashimoto’s thyroiditis) with 125 Ⅰ sICAM 1 RIA established in our lab Methods Using 125 Ⅰ sICAM 1 RIA, serum sICAM 1 levels of 400 healthy individuals as the normal group and 1020 patients with simple goitre (SG), Graves’ disease (GD) or Hashimoto’s thyroiditis (HT) were examined for a comporative chinical study Results The serum level of sICAM 1 ( ±s ) in the normal group was 168 43±36 23 μg/L There was no significant difference between the normal and SG groups ( P 】0 05), whereas the serum levels of sICAM 1 in autoimmune thyroid diseases (GD or HT) were higher than those in the normal or SG groups ( P 【0 05, respectively) After GD patients received one of three medical treatments, their serum sICAM 1 levels decreased ( P 【0 05) After GD patients were treated and their thyroid function decreased to normal, their serum sICAM 1 levels were lower than those in relapsed GD patients ( P 【0 05) Conclusions sICAM 1 RIA can be used to examine autoimmune thyroid diseases Serum levels of sICAM 1 can be used as a parameter in diagnosing autoimmune thyroid disease and in evaluating the effects of therapy, drug administration or relapse in GD